Giostarchicago

Call Us
Schedule Appointment

Dr. Anand Srivastava

About Dr. Srivastava

Scientific Publications

Stem Cell Journals

Scientific Achievements

Notable Positions

Reviewer Experience

Fellowships & Awards

Grants & Award Funding

Biological Techniques

Conference Appearances

Dr. Srivastava is a Chairman and Cofounder of the California-based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California (USA). Several governments and organizations – including the United States, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others – seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development, and its regulations.

The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson’s disease, Alzheimer’s disease, neuropathy, diabetes, heart disease, stroke, spinal cord injuries, paralysis, and blood related diseases. GIOSTAR is a leader in developing the most advanced stem cell based technology, supported by leading scientists with pioneering publications in the area of stem cell biology. The company’s primary focus is to discover and develop a cure for human diseases, with state-of-the-art, unique stem cell based therapies and products. Regenerative medicine provides promise for treatments of diseases previously regarded as incurable.

Click here for a PDF version of Dr. Anand’s publications and achievements.

Scientific Publications

  1. Cardiovascular diseases: Recent developments in regenerative medicine. Mahmood, A., Pandya, H., Rajasekar, S., Patel, D., Srivastava .. Journal of Stem Cell Research & Therapeutics. 2017, July 3(2):00095. doi: 10.15406/jsrt.2017.03.00095.
  2. Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice. Sharma V, Nayak J, DeRossi C, Charbono A, Ichikawa M, Ng BG, Grajales-Esquivel E, Srivastava A, Wang L, He P, Scott DA, Russell J, Contreras E, Guess CM, Krajewski S, Del Rio-Tsonis K, Freeze HH. FASEB J. 2014 Apr 28(4):1854-69. doi: 10.1096/fj.13-245514.
  3. Basal expression of pluripotency-associated genes can contribute to stemness property and differentiation potential. Dadheech N, Srivastava A, Belani M, Gupta S, Pal R, Bhonde RR, Srivastava AS, Gupta S. Stem Cells Dev. 2013 Jun 15;22(12):1802-17. doi: 10.1089/scd.2012.0261.
  4. Therapeutic potential of mesenchymal stem cells in regenerative medicine. Patel DM, Shah J, Srivastava AS., Stem Cells Int. 2013 Feb 496218. doi: 10.1155 / 2013 / 496218.
  5. Mannose supplements induce embryonic lethality and blindness in phosphomannose isomerase hypomorphic mice. Vandana Sharma, Jonamani Nayak, Charles DeRossi, Adriana Charbono, Mie Ichikawa, Bobby Ng, Erika Esquivel, Anand Srivastava, Ling Wang, Ping He, Joseph Russell, Emily Contreras, Cherise Guess, Stan Krajewski, Katia Del Rio-Tsonis, Hudson H Freeze; Journal Clin. Invest. (Communicated 2013).
  6. Srivastava AS, Stem cells., Curr Top Med Chem.;11:1591, 2011.
  7. Dhawan P, Ahmad R, Srivastava AS, Singh AB., Cancer stem cells and colorectal cancer: an overview. Curr Top Med Chem. 11:1592-8, 2011.
  8. Sudip Mandal, Anne Lindgren, Anand Srivastava and Utpal Banerjee. Role of mitochondria in self-renewal, early differentiation and tumorigenicity of pluripotent stem cell. Stem Cells, 29:486-95, 2011.
  9. Basak GW, Yasukawa S, Alfaro A, Halligan S, Srivastava AS, Minev B, Carrier E. Human embryonic stem cells hemangioblast express HLA-antigens. J Transl. Med., 7:27-36; 2009.
  10. Grzegorz Wladyslaw Basak, Srivastava AS, Rakesh Malhotra, Ewa Carrier. Multiple Myeloma Bone Marrow Niche. Curren. Pharm. Biotech, 10:345-6, 2009.
  11. Srivastava AS, Malhotra R, Jason Sharp and Berggren T. Potentials of ES Cell therapy in Neurodegenerative Diseases. Curren. Pharm. Design, 14:3873-9; 2008.
  12. Anand S. Srivastava, Rangnath Mishra, Sharmeela Kausal, Dharam P. Chauhan and Ewa Carrier; Clinical Prospects of Embryonic Stem Cells in treatment of Hematopoietic Disorders. Curren. Pharm. Biotech. 8: 51-56, 2007.
  13. Anand S. Srivastava, Elena Nedelcu, Babak Esmaeli-Azad, Rangnath Mishra and Ewa Carrier; Thrombopoietin Enhances Generation of CD 34+ Cells from Human Embryonic Stem Cells. Stem Cells, 25:1456-61, 2007.
  14. Anand S. Srivastava, Dharam Chauhan, Zong Ling Feng, Hyun S Kim and Ewa Carrier; Transplantation of embryonic stem cell in CDIL10-/- KO mouse, an animal model of colitis, antagonizes the manifestation of Crohn’s Disease. BBRC 361:953-959, 2007.
  15. Anand S. Srivastava, Steve Shenouda, Rangnath Mishra and Ewa Carrier; Transplanted Embryonic Stem cells Successfully Survive and Proliferate in Brain and Migrate to Damaged Regions of the Brain. Stem Cells, 24:1689-94, 2006.
  16. Anand S. Srivastava, Sharmeela Kaushal, Rangnath Mishra, Thomas A. Lane and Ewa Carrier; Dexamethasone facilitates erythropoiesis in murine embryonic stem cell differentiating into hematopoeitic cells in vitro. BBRC, 346:508-16, 2006.
  17. Marta R., Mara G., Srivastava A.S., Matthew, C. W., Kilian S., Carrier E., and Zanetti M.; Immunity over tolerance targeting fetal liver B cells. Vaccine, 23:4273-82, 2005.
  18. Feng Z, Srivastava AS, Mishra R, Carrier E., A regulatory role of Wnt signaling pathway in the hematopoietic differentiation of murine embryonic stem cells. Biochem. Biophys. Res. Commun., 324:1333-9, 2004
  19. Srivastava A.S., Chauhan, D.P. and Carrier E.; In utero detection of T7 phage in the fetal tissues after systemic administration to pregnant mice. Biotechniques, 37:81-83, 2004.
  20. Srivastava A.S., Kaido T., Carrier E.; Immunological factors that affect the in vivo fate of T7 phage in the mouse. J of Virol. Meth., 115:99-104, 2004.
  21. Srivastava A.S, G. Radhakrishna Pillai, Dharam P. Chauhan and Ewa Carrier; Induction of apoptosis in human lung cancer cells by dietary Curcumin. Cancer Letters, 208:163-170, 2004.
  22. M. E. Moustafa, A. S. Srivastava, E. Nedelcu, S. Shenouda and E. Carrier; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. Transplantation, 78:1274-1282, 2004.
  23. A. S. Srivastava, M. E. Moustafa, S. Shenouda, D. P. Chauhan and E. Carrier; In utero gene therapy: prospect and future. Curren. Pharm. Des., 10:3663-72, 2004.
  24. Anand S. Srivastava, Ichiro Oohara, Tohru Suzuki, Steve Shenouda, Surender N. Singh, Dharam P. Chauhan and Ewa Carrier; Purification and properties of cytosolic alanine aminotransferase from the liver of two fresh-water fish species, Clarias batrachus and Labeo rohita. Comp. Biochem. Physiol-B, 137:197-207, 2004.
  25. Suzuki,T., Srivastava, A.S. and Kurokawa,T., Paralichthys olivaceus COL1A1 mRNA for type 1 collagen alpha 1, complete cds. Nat. Cent. Biotech. Infor., USA, AB196513, 2004.
  26. Suzuki,T., Srivastava, A.S. and Kurokawa,T., Paralichthys olivaceus COL1A2 mRNA for type 1 collagen alpha 2, complete cds. Nat. Cent. Biotech. Infor., USA, AB196514, 2004.
  1. Suzuki,T., Srivastava, A.S. and Kurokawa,T., Paralichthys olivaceus COL1A3 mRNA for type 1 collagen alpha 3, partial cds. Nat. Cent. Biotech. Infor., USA, AB196515, 2004.
  2. Suzuki,T., Srivastava, A.S. and Kurokawa,T., Paralichthys olivaceus COL1A1 gene for type 1 collagen alpha 1, promoter region. Nat.Cent. Biotech. Infor., USA, AB196516, 2004.
  3. Suzuki,T., Srivastava, A.S. and Kurokawa,T., Paralichthys olivaceus COL1A3 gene for type 1 collagen alpha 3, promoter region. Nat. Cent. Biotech. Infor., USA, AB196517, 2004.
  4. Srivastava A.S., Kurokawa T., Suzuki T.; Molecular cloning and cDNA sequence analysis of carboxypeptidases A1, A2 and B from the Japanese flounder Paralichthys olivaceus. Comp. Biochem. Physiol-B, 135:593-599, 2003.
  5. Hassan S., Jody D., Gilpin E.A., Srivastava A.S., Carrier E.; Tolerance and immunity following in utero transplantation of allogeneic fetal liver cells: The cytokine shift. Cell Transplantation, 12:75-82, 2003.
  6. Tohru Suzuki, Anand S. Srivastava, Tadahide Kurokawa; A homologue of human placental protein, PP11, and mouse T cell-specific, Tcl-30, in exocrine pancreas of a teleost Paralichthys olivaceus. Comp. Biochem. Physiol-B, 133:325-329, 2002.
  7. Anand S. Srivastava, Tohru Suzuki, Tadahide Kurokawa; mRNA expression of pancreatic enzyme precursors and estimation of protein digestibility in first feeding larvae of the Japanese flounder, Paralichthys olivaceus. Comp. Biochem. Physiol-A, 132:629-635, 2002.
  8. Hassan S., Jody D., Srivastava A.S., Gilpin E., Lee T, Carrier E.; Alloreactivity following in utero transplantation of cytokine-stimulated hematopoietic stem cells: The role of recipient CD4- cells. Exp. Hematol., 30:617-624, 2002.
  9. Tohru Suzuki, Anand S. Srivastava, Tadahide Kurokawa; cDNA Cloning and phylogenetic analysis of pancreatic serine proteases from Japanese flounder, Paralichthys olivaceus. Comp. Biochem. Physiol-B, 131:63-70, 2002.
  10. Suzuki, T., Srivastava, A.S. and Kurokawa, T; Paralichthys olivaceus ppsb mRNA for pancreatic protein with two somatomedin B domains. Nat. Cent. Biotech. Infor., USA,AB035673, 2002.
  11. Tohru Suzuki, Tadahide Kurokawa, Anand S. Srivastava; Induction of bent cartilaginous skeletons and undulating notochord in flounder embryos by disulfiram and α, ά- Dipyridyl. Zoological Science, 18:345-351, 2001.
  12. Tohru Suzuki, Nobuo Suzuki, Anand S. Srivastava, Tadahide Kurokawa; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Bichem. Bio. Res. Commu. 270:40-45, 2000.
  13. Suzuki, T., Suzuki, N., Srivastava, A.S and Kurokawa, T; Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete sequence. Nat. Cent. Biotech. Infor., USA, AB037673, 2000.
  14. Suzuki, T., Suzuki, N., Srivastava, A.S and Kurokawa, T;Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete sequence. Nat. Cent. Biotech. Infor., USA, AB037674, 2000.
  15. Suzuki,T. and Srivastava, A.S; Keratin expressed at esophagus and skin of flounder larvae. Nat. Cent. Biotech. Infor., USA, AB049616, 2000.
  16. Suzuki T., Srivastava A.S., Kurokawa T.; Experimental induction of jaw and gill skeletal malformation in Japanese flounder, Paralichthys olivaceus, larvae. Aquaculture, 185: 175-187, 2000.
  17. Suzuki T., Srivastava A.S., Kurokawa T.; Hoxb-5 is expressed in gill arch 5 during pharyngeal arch Development of flounder Paralichthys olivaceus embryos. Int. J. Dev. Biol, 43:357-559, (1999).
  18. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 1. Nat. Cent. Biotech. Infor., USA, AB029750, (1999).
  19. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 2. Cent. Biotech. Infor., USA, AB029751, (1999).
  20. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for trypsinogen 3. Cent. Biotech. Infor., USA, AB029752, (1999).Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 1. Cent. Biotech. Infor., USA, AB029753 (1999).
  21. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for chymotrypsinogen 2. Cent. Biotech. Infor., USA, AB029754 (1999).
  22. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 1 precursor. Cent. Biotech. Infor., USA, AB029755, (1999).
  23. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 2 precursor. Cent. Biotech. Infor., USA, AB029756, (1999).
  24. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 3 precursor. Cent. Biotech. Infor., AB029757, (1999).
  25. Suzuki T., Srivastava A.S., Kurokawa T.; Japanese flounder mRNA for elastase 4 precursor. Cent. Biotech. Infor., USA, AB029758, (1999).
  26. Srivastava A.S., Oohara I., Suzuki T., Singh S.N.; Activity and expression of aspartate aminotransferase during reproductive cycle of a fresh water fish, Clarias batrachus. Fish Physiol. Biochem., 20:243-250,1999.
  27. Srivastava A.S., Oohara I., Suzuki T., Singh S.N.; Activity and expression of Glutamate Oxaloacetate Transaminase during reproductive cycle of a fresh water fish Labeo rohita. Fisheries Science, 64(4):621-626,1998.
  28. Srivastava A.S., Trigun S.K., Singh S.N.; Activity of cytosolic and mitochondrial alanin aminotransferase during pre-spawning phase in air-breathing and non air-breathing fishes. J. Sci. Res., 47:33-38,1997.

Back to Top

Stem Cell Journals

  1. Current Topics of Medicinal Chemistry (recognized as being among the top five medicinal chemistry journals) devoted its special issue on stem cells to Dr. Srivastava in 2010.
  2. Stem Cell International devoted its special issue on stem cells to Dr. Srivastava in 2012.
  3. Potentials of ES Cell Therapy in Neurodegenerative Diseases (Curr Pharm Des; 2008;14:3873-9) by Dr. Srivastava still holds the number one position among the top 20 articles published since 2008 in the field rated by BioMedLib in 2012.

Scientific Achievements

  1. Srivastava developed the animal material free and serum-free Human Embryonic Stem (ES) cell culture condition to use Human ES cells to treat human diseases.
  2. Dr. Srivastava for the first time showed that if ES cells injected into developing fetuses in utero participate in development of all body of a living organism.
  3. For the first time, he showed that ES cells are better accepted by the transplanted animals in comparison to adult stem cells.
  4. For the first time, he showed the way to generate a high number of pre-erythrocytes using glucocorticoid hormone; this may be used to treat several blood diseases.
  5. For the first time, using ES cells he generated a high number of CD34+ expressing a kind of hematopoietic stem cell which can be used to treat several autoimmune diseases, immune reconstitution and blood diseases.
  6. For the first time, he showed the molecular mechanism behind the regulation of ES cell differentiation into hematopoietic cells.
  7. For the first time, he showed that ES cells automatically recognize the damaged portion of the brain, and can be used to repair the damaged brain.
  8. For the first time, he showed that ES cell can be used to treat Crohn’s disease (an inflammatory bowel disease that may develop into colon cancer).
  9. For the first time, he demonstrated that mammalian fetuses can be programmed inside the mother’s uterus to face the challenges of future possible infection. This finding is very important in the development of advanced therapy for cancer, AIDS, and many other fatal diseases. Utilizing these techniques, fetuses can be given information about all possible infections, providing the capability to counter those infections and diseases.
  10. He has demonstrated for the first time that it is easy to correct the genetic diseases in developing fetus in utero in comparison to adult animals.
  11. He has shown for the first time that the lung cancer cells can be treated with the help of plant product curcumin, and can be used as an effective cancer therapeutic agent. He also demonstrated that how curcumin regulated the genes related to programmed death of cancerous cell – a finding that will aid in the development of non-toxic, less expensive, easily available drug for cancer.
  12. The biggest problem in the treatment of cancer and other diseases is the non-specific distribution of medicine and toxic chemotherapeutic agents to healthy tissues. Dr. Srivastava for the first time developed a technique that can help in targeting diseased tissues using the tissue receptor binding peptide ligands. These techniques can be used for targeted delivery of drugs and genes (in case of genetic disease) to the specific fetal tissues inside the mother uterus, without harming the normal tissues of mother and fetus.
  1. For the first time, he demonstrated the insertion of foreign pancreas enzyme specific gene promoter into developing animals embryos, and successfully showed the incorporation and regulation of pancreatic enzymes in the control of the inserted gene. This is a very important finding and proves that the defective genes can be replaced easily and effectively by the normal functional genes during the development of animals. This finding will help in the change of defective genes of insulin hormone, which is present in the pancreas of patients suffering from diabetes and many other genetic diseases.
  2. For the first time, he reported the gene sequence of all important pancreatic enzymes (three isoforms of trypsinogen, two isoforms of chymotrypsinogen, four types of elastases, three forms of carboxypeptidases and lipase) and its evolutionary relationship with the human. Also, he reported first time the regulation of digestion by these enzymes in the alimentary canal during digestion of proteins in the developing animals.
  3. For the first time, he cloned and sequenced two types of human homologs of the Vitamin D receptor gene from Japanese flounder. This is the most important receptor, which helps in the development of bone. Before Dr. Srivastava’s report, characteristics of this gene were not known in Japanese flounder. This finding helped in the understanding of the genetic evolution of mammals.
  4. For the first time, he cloned and sequenced the homolog of human placental protein, PP11, and mouse T cell-specific, Tcl-30, in the pancreas of Japanese flounder. This study suggests that these genes evolved from the fish pancreas and in fish they help in synthesizing the digestive enzymes. During their evolution, however, their function got changed, causing them to work differently in the mammalian placenta. This was a very important finding related to this rare gene.
  5. For the first time, he has shown that the Hox and sonic hedgehog genes regulate the development of bones and respiratory organs. He also demonstrated that these genes could be regulated artificially. This was a very important finding, since it provides insights into how genes regulate the development of organs.
  6. For the first time, he purified and characterized the human homologs of AAT and ASPT enzymes. These are the basic clinical marker in all infection, and the major marker of liver function test.
  7. For the first time, he demonstrated the coordination of AAT and ASPT enzymes in the production of energy through amino acids after aerobic respiration.
  8. For the first time, he has shown that according to the metabolic demand of the body AAT and ASPT genes synthesized additional forms of its isoform to cope up with the extra energy demand and work as an “on” and off” switch. 

Back to Top

Notable Positions

  1. Chairman & Cofounder: Global Institute of Stem Cell Therapy and Research (GIOSTAR), San Diego, CA. USA.
  2. Visiting Associate Researcher: Department of Molecular, Cell and Development Biology, University of California Los Angeles (UCLA), CA, USA.
  3. Visiting Researcher: Department of Stem Cell Biology, Sanford Burnham Prebys Medical Discovery Institute, San Diego, CA, USA.
  4. Senior Scientist: Stem Cell Core Facility, The Salk Institute of Biological Studies, La Jolla, CA, USA.
  5. Associate Project Scientist: Department of Stem Cells and Neurology, School of Medicine, University of California Irvine (UCI), Irvine, CA, USA.
  6. Assistant Project Scientist: Cancer Center, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
  7. Visiting Fellow: National Research Institute (NRI), Nansei, Mie, Japan.

  1. Additionally, Dr. Srivastava has contributed to stem cell programs, and has guided stem cell policies and programs for the following governments and private organizations:

    1. Helped stem cell core facility at The Salk Institute of Biological Studies, San Diego, USA
    2. Worked for the stem cell program at the University of California, Los Angeles (UCLA), USA
    3. Worked for Japanese Research Institute (JRI) for developing the genomic program, Japan
    4. Guided scientists in developing stem cell programs for Turkey, Kuwait and Saudi Arabia
    5. Stem Cell Program Director of GIOSTAR for the State of Gujarat, India
    6. Stem Cell Program Director of GIOSTAR for the State of Madhya Pradesh, India
    7. Stem Cell Program Director of GIOSTAR for the State of Chhattisgarh, India
    8. Stem Cell Program Director of GIOSTAR for University of Baroda, Gujarat, India
    9. Stem Cell Program Advisor for Asian Medical Institute, Kyrgyzstan 

Back to Top

Reviewer Experience

Dr. Srivastava is a member of several scientific review committees, and is closely involved in reviewing research grants. He has written several review articles and scientific manuscripts. He is also the reviewer of several scientific journals, including:
  1. Advances in Stem Cells
  2. Current Pharmaceutical Design
  3. Current Topics in Medicinal Chemistry
  4. Stem Cells
  5. Stem Cell International
  6. Current in Cell Medicine
  7. Journal of Stem Cell Research and Therapy
  8. Conference Papers in Molecular Biology
  9. Journal of Pharmaceutics
  10. Current Pharmaceutical Biotechnology
  11. Open Journal of Organ Transplant Surgery
  12. Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry‏
  13. Stem Cells and Cloning: Advances and Applications
  14. Blood and Lymphatic Cancer: Targets and Therapy
  15. Degenerative Neurological and Neuromuscular Disease
  16. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
  17. Immuno Targets and Therapy
  18. Current Vascular Pharmacology
  1. Gastrointestinal Cancer: Targets and Therapy
  2. Journal of Bioengineering and Biomedical Sciences
  3. The Application of Clinical Genetics
  4. Journal of Tissue Science & Engineering
  5. Neuropsychiatric Disease and Treatment
  6. Current Tissue Engineering
  7. Hepatic Medicine: Evidence and Research
  8. Current Drug Discovery Technologies
  9. Current Bioactive Compounds
  10. Transplant Research and Risk Management
  11. Biosimilars
  12. Current Drug Delivery
  13. Journal of Experimental Pharmacology
  14. Open Journal of Regenerative Medicine
  15. Current Diabetes Reviews
  16. Journal of Fertilization: In Vitro
  17. Clinical and Translational Medicine

Back to Top

Fellowships & Awards

2003

Awarded with the “National Integrated Medical Association (NIMA) Outstanding Scientist” award from NIMA, India.

2003

Awarded with the “Excellent Scientist Award” from Bharat Vikas Parisad, India for continuous excellent performance in the life science research.

2003

The 18th International Congress of Clinical Chemistry and Laboratory Medicine Kyoto “Excellent Poster Award,” Kyoto, JAPAN.

2002

“Best Scientist Award” for excellent contribution in the field of life science research from Kayastha Maha Sabha, Varanasi, India.

1998-2000

“Long-term STA/JISTEC Award” (Science and Technology Agency/Japan International Science and Technology Exchange Center, Japan)
Fellowship award for two years from the government of JAPAN.

1997-1998

“Short-term STA/JISTEC Award” (Science and Technology Agency/Japan International Science and Technology Exchange Center, Japan) Fellowship award for three months from the government of JAPAN (October 1997- January 1998).

1997-1998

Awarded with the “Research Associate-Ship Award” from the Council of Scientific and Industrial Research (CSIR) Government of India.

1990-1995

“CAS (Center of Advanced Study) Award” in Zoology.
Doctoral research fellowship award from the Government of India.Â

Back to Top

Grants & Award Funding

  1. Government of India grant to establish Red Blood Cell from Stem Cell (2015-2017).
  2. Canada Grand Challenge Grant Award, Canada, Development of Tuberculosis (TB) test in TB patients (2013-2014).
  3. Government of India grant to establish stem cell transplant center (2009-date).
  4. Broad Medical Research Program, Repair of Crohn’s Disease with Stem Cells, (2004-2005).
  5. National Institute of Health, USA (NIH/NIDDK R01 grant), Mixed Chimerism Following Prenatal Tolerance Induction, (1999-2005).
  6. Ronald McDonald House Charities Medical Grant, Lentiviral Gene Transfer in ß-Thalassemic Mice, (2000-2005).
  7. National Institute of Health, USA (NIH-K08 grant), in utero transplantation of stem cell in ß-Thalassemic mice, (2000-2002).
  8. Japan Science and Technology award (JISTEC Grant), Government of Japan, Cloning and gene expression during development (1988-2000).
  9. Japan Science and Technology award (JISTEC Grant), Government of Japan, Expression of enzymes and protein during energy metabolism (1997-1998).
  10. Center of Scientific and Industrial Research (CISR) grant, Government of India under young scientist award (1996-1997).

 

Back to Top

Biological Techniques

Human Embryonic Stem cell culture, Serum-free and feeder-free hES cell culture, in vitro differentiation of hES cells into neural cells, in vitro differentiation of hES into hematopoietic cells and red blood cells under the control of cytokines. Gene regulation studies using RT-PCR, Real-time PCR, Northern blot, Southern blot and in situ hybridization, immunohistochemistry during the differentiation, Cell cycle regulation studies during differentiation of hES cells into hematopoietic and neural cells. Use of siRNA for blocking a specific cell cycle. FACS analysis of differentiated cells and cell shorting. ES cell transfection.

In Vivo Studies With ES Cells

  • Dr. Srivastava reated a mouse model for studying the effect of ES cells on a damaged brain. Injection of ES cells into a mouse brain, tail vein injection, in vivo tracking of ES cell migration. Used the ES cells for repair of damaged brain. Gene and protein regulation during neural cell differentiation. Studies on transcription factors. Histochemical analysis of transplanted ES cells using fluorescent, confocal microscopy and deconvolution microscopy.
  • Dr. Srivastava created a mouse model for Crohn’s disease. In vivo migration of ES cells into diseased portion of intestine. Studies on inflammatory cytokines during the repair of Crohn’s disease with ES cell. Gene regulation studies during this process. Elisa assays for the cytokines. Stem cell niche interaction.
  • Dr. Srivastava created in utero mouse model for ES cells transplantation. Used this model to make chimeric animals. Distribution and differentiation of ES cells into developing mouse embryo. FACS and magnetic shorting of ES cells derived CD31+, CD34+, CD45+ cells from the transplanted animal tissues. Gene and protein regulation of in vivo differentiating cells.
  • Dr. Srivastava created an immunocompromised mouse model to study the effect of in vivo immune component on T7 phage virus. In vivo selection of tissue-specific receptor binding peptide using in vivo biopanning method. Tissue targeted gene delivery to correct the blood related genetic diseases. Gene cloning, gene sequencing, synthesis of RNA probes.

Protein And Enzyme Biochemistry

Protein assay, peptide structure, amino acid sequencing, Enzyme assay, Ultracentrifugation, Ion exchange chromatography, column chromatography, HPLC, and Protein and gene regulation during the development. Enzyme kinetics, Enzyme inhibition, SDS gel electrophoresis, Protein characterization.

Selection Of Cell Receptor Binding Peptide And Phage Display Technology

  • Selection of tissue receptor binding peptides using T7 phage display system.
  • In vivo and in vitro biopanning for selection of receptor binding peptides sequences.
  • Characterization of targeted cells and tissues using histochemistry and gene expression analyses.
  • In vivo delivery of drugs and genes to targeted tissues using microinjection.

Cancer Research

  • Studying the role of pharmaceutical agent curcumin as an anti-lung cancer drug and development of the agent as a non-toxic cancer drug.
  • Role of apoptotic genes on the lung cancer cell lines.
  • Development of tissue targeted delivery protocol of pharmaceuticals agents for cancer and genetic diseases.

Fluorescence Techniques For Nucleic Acid Sequence Detection: Clinical And Diagnostic Applications

  • Fluorescent labeling of DNA and RNA probes.
  • Fluorescence Resonance Energy Transfer (FRET) protocols for DNA and RNA sequence.
  • Detection in real time (Sequence Detection System 7700, ABI, Perkin Elmer).
  • FRET protocols for monitoring ribozyme reactions and kinetics in real time (TaqMan, SDS 7700, ABI, Perkin Elmer).
  • Accessibility studies for DNA and RNA target sequences using FRET.
  • Fluorescence polarization protocols for monitoring ribozyme reactions (POLARstar, BMG, GmbH) and for DNA and RNA sequence detection.
  • Sequence detection with Syber green dye in real time quantitative PCR by Light Cycler (Roche Diagnostics, USA).
  • Single nucleotide polymorphism detection in real time with LightCycler hybridization probes (Roche Diagnostics, USA).

Cancer Research

  • Preparation of radio-labeled & fluorescent labeled RNAs (ribozymes and target substrates).
  • In vitro transcription of RNA.
  • Expression of ribozymes in yeast.
  • Isolation and purification of cellular RNA.
  • RNase Protection Assay.
  • Kinetic characterization of ribozymes & binding kinetics using fluorescence methods.
  • Designing, synthesis and characterization of allosteric ribozymes induced by small drug ligands (such as theophylline & caffeine).
  • Developed in utero microinjection techniques to transplant the bone marrow and stem cells to cure blood related genetic disease.
  • Harvest fetal liver, bone marrow and mouse embryonic stem cells for transplantation.
  • Culture mouse embryonic stem cell and in vitro differentiation into the blood cells.
  • Fractionation of cells using flow cytometry techniques.

Fluorescence Techniques For Nucleic Acid Sequence Detection: Clinical And Diagnostic Applications

  • Standard and site directed mutagenesis polymerase chain reaction (PCR).
  • Preparation and purification of plasmids.
  • Transformations and Transfection of DNA.
  • Cloning of DNA.
  • Solid phase synthesis of DNA (Gene Assembler, Pharmacia).
  • DNA sequencing & fragment analyses (ABI 310 Gene Sequencer, Perkin Elmer).
  • Quantitation of DNA, RNA and proteins.
  • Mammalian cell culture and yeast culture.
  • Gel electrophoresis (polyacrylamide and agarose).
  • Capillary gel electrophoresis (ABI 310 Gene Sequencer, Perkin Elmer).
  • Column/ gel / thin layer chromatography.
  • Autoradiography by phosphorimager (Storm, Molecular Dynamics, USA).
  • High Performance Liquid Chromatography (HPLC).
  • Preparation and purification of chemical reagents & solvents.
  • Enzyme/ protein/ purification and characterization.
  • Isolation of Genomic DNA, Genomic Library Construction.
  • Radioimmunoassay.

General Molecular And Biochemical Techniques

mRNA preparation and purification, Primer designing, Real-time PCR, RT-PCR, DNA cloning, DNA sequencing, Isolation of Genomic DNA, Genomic library Construction, Transformation, Transfection, Cell culture, Plasmid purification, RNA probe making, Different kinds of microscopy, In situ hybridization, Southern blotting, Northern blotting, Western blotting, Spectrophotometery, In uteromicroinjection, Column chromatography, HPLC, PAGE, Agarose gel-electrophoresis, Enzyme assay, Protein assay, Enzyme/ Protein/ DNA purification, Histology, Phage display for tissue targeting, Radio-immunoassay.

Autologous Stem Cell Transplant Techniques

Developed the techniques to isolate the autologous stem cell from patient’s peripheral blood, bone marrow or fat tissues, characterize and activate those stem cells so they can be effectively used for the treatment of specific diseases.

Back to Top

Conference Appearances

  1. Srivastava A.S. Invited to chair the session at 8th Annual World Congress of Regenerative Medicine & Stem Cell-Korea at Busan,South Korea. March 2015.
  2. Srivastava A.S. Invited Speaker 5th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery System at Dubai, UAE. March 2015. 
  3. Srivastava A.S. 4th International Conference on Neurology and Epidemiology at Malaysia, Kuala Lumpur, November 2014.
  4. Srivastava A.S. Invited Speaker, 3rd International Conference on Translational Medicine at Las Vegas, USA. November 2014.
  5. Srivastava A.S. 7th Annual Clinical Trials on Alzheimer’s Disease at Philadelphia, USA. November 2014.
  6. Srivastava A.S. 4th World Congress on Cell Science & Stem Cell Research at Valencia, Spain. June 2014.
  7. Srivastava A.S. Invited Speaker, STEM 2013, 9th Annual Conference on Biotechnology – Focusing On Latest Trend in Stem Cells, Regenerative Medicine and Tissue Engineering at Mumbai, India. January 2013
  8. Srivastava A.S. International Conference on Regenerative and Functional Medicine (Regenerative Medicine-2012), San Antonio, USA. November 2012.
  9. Srivastava A.S. 2nd International Congress on Neurology & Epidemiology; Impact of drugs on the natural history of neurological diseases at Nice, France. November 2012.
  10. Srivastava A.S. Invited Speaker, International Expo and Conference on Analytrix & HPLC at Chicago, USA. October 2012.
  11. Srivastava A.S. Invited Speaker International Conference on Emerging Cell Therapies (Cell Therapy-2012) at Chicago, USA. October 2012.
  12. Srivastava A.S. Invited Speaker, 6th Neurodegenerative Conditions Research and Development Conference at San Francisco, CA, USA. September 2012
  13. Srivastava A.S. 8th International Congress on Mental Dysfunction & Other Non-Motor Features in Parkinson’s Disease and Related Disorders at Berlin, Germany. May 2012
  14. Srivastava A.S. International Conference and Exhibition on Neurology & Therapeutics at Las Vegas, USA. May 2012.
  15. Srivastava A.S. Montreal International Biotechnology Forum at Montreal, Quebec, Canada. May 2012.
  16. Srivastava A.S.  Invited Speaker, International Association of Neurorestoratology (IANR) V and 9th Global College Neuroprotection and Neuroregeneration (GCNN) conference with the 4th International Spinal Cord Injury Treatment & Trial Symposium (ISCITT), Xi’an City, China. May 2012.
  17. Srivastava A.S. International Forum on the Mediterranean Diet, Ravello – Amalfi Coast, Italy. March 2012
  18. Srivastava A.S. Hong Kong International Stem Cell Forum 2012, Hong Kong. February 2012.
  19. Srivastava A.S. 4th International Conference on Drug Discovery and Therapy (4th ICDDT 2012) at Dubai, UAE, February 2012.
  20. Srivastava A.S. Evolving Strategies in Hematopoietic Stem Cell Transplantation at San Diego, USA. February 2012.
  21. Srivastava A.S. Hebei International Biotechnology Forum; Shijiazhuang, Hebei, China. November 2011.
  22. Srivastava A.S. 3rd International Conference on Drug Discovery and Therapy. Regenerative Medicine at Dubai, UAE. February 2011.
  23. Srivastava A.S. 3rd Annual Congress of Regenerative Medicine & Stem Cell-2010 at Shanghai, China. December 2010.
  24. Srivastava A.S. 1st Annual Tetra-Congress of MolMed-Personalized Medicine Congress 2010 at Shanghai, China. November 2010.
  25. Srivastava A.S. International Association of Neurorestoratology(IANR), American Journal of Neuroprotection and Neuroregeneration at Beijing, China. October 2010.
  26. Srivastava A.S. EPS Global International Neuroscience Forum at Nha Trang, Vietnam. October 2010.
  27. Srivastava A.S. EPS Global International Neuroscience Forum at Guangzhou, China. September 2010.
  28. Srivastava A.S. 4th Academic Congress of International Chinese Neurosurgical Sciences at Chengdu, China. June 2010.
  29. Srivastava A.S. 1st Annual World Congress of Immunodiseases and Therapy (WCIT 2010) at Beijing, China. May 2010.
  30. Srivastava A.S. 3rd PepCon-2010 – Protein Misfolding and Neurodegeneration at Beijing, China. March 2010
  31. Srivastava A.S. Potential use of ES cells in hematopoietic and neural diseases at City of Hope National Medical Center, Duarte, California, USA. January, 2009.
  32. Srivastava A.S. Differentiation of Human Embryonic Stem cell into erythrocyte and neural precursor cells: Its potential application at Cleveland Clinic, Cleveland, Ohio, USA, December, 2008.
  33. Srivastava A.S. Potential of ES cell in repair of Hematopoietic and neural diseases. International Conference in Stem Cell, Kerala, India. August 2008.
  34. Srivastava A. S., Singh U. and Carrier E. Embryonic stem cell improve colitis and decrease IL-12 levels in the colitis mice. BMRP Fourth Annual Investigator Meeting, Los Angeles, USA. 2006
  35. Carrier E., Shermila Kausal and Srivastava A. S. Gene Regulation During the Erythrocytic Differentiation of Embryonic Stem Cells. Blood (ASH Meeting), 2005.
  36. Carrier E., Shermila Kausal and Srivastava A. S. Differentiation of Human ES cell into the Hemangioblast. Blood (AHS Meeting), 2005.
  37. Srivastava A.S., Zhongling F., Victor A., Kim H.S. and Carrier E. Repair of Crohn’s disease with embryonic stem cells. Broad Medical Research Program, Third Annual Investigator Meeting at Los Angeles, CA, USA, 2005.
  38.  
  1. Srivastava A.S., Shenouda S. and Carrier E. Damaged murine brain induces ES cells into migration and proliferation. Blood:104, 779a, 2004.
  2. Srivastava A.S., Shenouda S. and Carrier E. Increased expression of OCT4,SOX2 and FGF4 genes following injection of embryonic stem cell into damaged murine brain. American Society of Gene Therapy, 2004.
  3. Srivastava A.S. and Carrier E.; Distribution and stability of T7 phage in mouse blood and tissues. Molecular Therapy:7, 230, 2003.
  4. Moustafa M., Srivastava A.S., Nedelcu E., Minev B., Carrier E.; Chimerism and tolerance post in utero transplantation with ontogenically different sources of stem cells. 32nd annual meeting of the international society for Experimental Hematology, 31, 274, 2003 (Paris, France).
  5. Steve S., Srivastava A.S. Carrier E.; In vivo survival of hematopoietic stem cell in mouse brain. 11th International Symposium on Recent Advances in Stem cell Transplantation, 89-90, 2003 (San Diego, USA).
  6. Srivastava A.S., Carrier E.; Distribution and stability of T7 phage in mouse. 11th international symposium on recent advances in Stem cell transplantation, 93, 2003 (San Diego, USA).
  7. Elena N., Srivastava A.S., Varki N.M., Assatourian G. and E. Carrier; Embryonic stem cells survive and proliferate after intraperitoneal In utero transplantation and produce teratocarcinomas. Blood:160b, 2002.
  8. Srivastava A.S and E. Carrier; In utero targeting the fetal liver by using T7 phage display system. Blood:489b, 2002.
  9. Srivastava A.S. and E. Carrier; Factor responsible for in vivo neutralization of T7 phage display vector in the blood of mice. Blood:489b, 2002.
  10. Srivastava A.S. and E. Carrier; Distribution and stability of T7 phage in the mouse after intravenous administration. ICCC, Kyoto, JAPAN. (October 2002).
  11. Srivastava A.S., T. Kaido and E. Carrier; Immunological factors that affect the in vivo fate of T7 phage in the mouse. Molecular Therapy:5, 713, 2002.
  12. Srivastava A.S., E. Nedelcu and E. Carrier; Engraftment of murine embryonic stem cells after in utero transplantation. Molecular Therapy:5, 1132, 2003.
  13. M. Rizzi, T. Kaido, M. Gerloni, K. Schuler, A. S. Srivastava, E. Carrier and M. Zanetti; Neonatal T cell immunity by in uteroimmunization. AAI 2002 annual meeting, April 20-24, New Orleans, Experimental Biology 2002 sponsored by 7 FASEB societies.
  14. Srivastava A.S., T. Kaido and E. Carrier; Kinetics of T7 phage neutralization in the blood of normal and immunodeficient mice. Blood:407, 2001.
  15. Hassan S., Jody D., Srivastava A.S., T.H. Lee, M.P. Busch, Carrier E.; Immunity without microchimerism after in utero transplantation of Hematopoietic stem cell. Blood:320, 2001.
  16. Srivastava A.S., Felix Tinkov, T. Friedmann and E. Carrier; Detection of T7 phage in the fetus after Systemic administration to pregnant mice. Molecular Therapy:4, 760, 2001.
  17. Pillai G.R., Srivastava A.S., Hassan S., Carrier E. Differential sensitivity of human lung cancer cell lines to curcumin. 9th Annual International Symposium on Recent Advances in Hematopoietic Stem cell Transplantation. USA. 2001.
  18. Hassan S., Jody D., Srivastava A.S., Carrier E.; The role of I-E molecule on survival rate and tolerance after in uterotransplantation. The 42 ASH meeting, San Francisco, USA. 2000.
  19. Suzuki T., Srivastava A.S., Kurokawa T.; Identification of cDNA encoding two subtypes of vitamin D receptor in flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, April 2-4, 2000, Tokyo, JAPAN.
  20. Srivastava A.S., Suzuki T., Kurokawa T., Kamimoto M., Nakatsuji T.; GFP expression in pancreas of developing fish embryo under control of Carboxypeptidase A promoter. Plant and Animal Genome-VIII (PAG-VIII), Conference, San Diego, California, USA. January 9-12, 2000.
  21. Srivastava A.S., Suzuki T., Kurokawa T.; Molecular cloning of serine protease cDNAs from pancreas of Japanese flounder, Paralichthys olivaceus. Meeting of the Japanese Society of Fisheries Science, Tokyo, JAPAN. 1999.
  22. Suzuki T., Srivastava A.S., Kurokawa T.; Cloning of FGFRs from flounder embryos, and their expression during axial skeletal development. 32nd Annual Meeting of the Japanese Society of Developmental Biologists. JAPAN. 1999.
  23. Suzuki T., Srivastava A.S., Kurokawa T.; Expression of Signal molecules during axial skeleton development in Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.
  24. Suzuki N., Suzuki T., Srivastava A.S., Kurokawa T.; cDNA cloning and expression analysis of receptor for calcitonin and calcitonin related peptide from Japanese flounder. Meeting of the Japanese Society of Zoological Science. JAPAN. 1999.
  25. Srivastava A.S., Trigun S.K., Singh S.N.; Purification and kinetics of cytosolic aspartate aminotransferase from liver of air-breathing and non air-breathing fish. National Symposium on Comparative Physiology & Endocrinology, Raipur, INDIA. 1997.
  26. Srivastava A.S., Trigun S.K., Singh S.N.; Cytosolic alanin aminotransferase from air-breathing and non air- breathing fish. Proceedings of the Symposium on Frontier Topics in Biochemistry and Molecular Biology, Banaras Hindu University, Varanasi, INDIA. 1996.
  27. Srivastava A.S., Trigun S.K., Singh S.N.; Studies on aspartate aminotransferase during reproductive cycle of C. batrachus and L. rohita. Proceeding of the 65th Annual Meeting of the Society of Biological Chemists, I.I.Sc., Bangalore, INDIA. 1996.
  28. Srivastava A.S., Singh S.N.; A comparison of cytosolic and mitochondrial aminotransferases in fishes. Proceedings of the 4th Convention of Indian Society of Agricultural Biochemist, Banaras Hindu University, Varanasi, INDIA. 1995.
  29.  

Back to Top